Antibodies, Effective in Preventing Symptomatic COVID-19 Infections?

While the world focuses on the rollout of COVID-19 vaccines, antibody treatments that can be given to patients after they've contracted the disease haven't been in the spotlight.

Regeneron's cocktail of two monoclonal antibodies synthesized to block the SARS-CoV-2 virus got plenty of press when it was given to President Trump, who subsequently recovered from COVID-19. In November 2020, Regeneron won emergency use authorization from the Food and Drug Administration for the cocktail, called REGN-COV2, in treating patients with mild to moderate cases of the disease. It also scored a contract with the U.S. government to supply 300,000 doses. That deal was just the beginning.

Check it right here.


© 2021 by Covid Plasma Initiative Foundation

The Yitzchok Lebovits COVID Plasma Initiative is dedicated in memory of R’ Yitzchok a"h Ben R’ Moshe Eliezer y"blt, who recently passed away. R' Yitzchok was a brother of Chaim Lebovits who has been a driving force behind every aspect of this initiative to bring this life-saving therapy to the people who need it.